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Introduction
The articular cartilage covers the articulating surface of bone 
elements, ensuring frictionless joint motion. Osteoarthritis 
(OA) is a leading cause of disability worldwide, affecting up 
to one third of the population over the age of 50 (Lawrence 
et al., 1998; Lawrence et al., 2008) and costing $185.5 mil-
lion only in the US (Kotlarz et al., 2009). Cartilage break-
down is the hallmark of OA. Unfortunately, no treatment 
for OA is currently available, except for pain control and 
physiotherapy, until prosthetic joint replacement is required. 
Understanding the pathogenetic mechanisms leading to the 
disruption of homeostasis and cartilage breakdown is of para-
mount importance to the development of effective pharmaco-
logical treatments.
Degeneration of the articular cartilage is the final outcome 
of an imbalance between catabolic processes triggered by inju-
rious factors (biomechanical or inflammatory) and compensa-
tory anabolic processes. Genetic studies in humans (Loughlin 
et al., 2004) and experimentation in animal models (Lories 
et al., 2007; Wu et al., 2010) have convincingly demonstrated 
the involvement of Wnt signaling in OA pathogenesis.
Wnts are a family of 19 morphogens involved in several 
processes from embryonic morphogenesis to homeostasis of 
adult tissues (Logan and Nusse, 2004). Wnts signal through 
multiple pathways (Macdonald et al., 2007; Semenov et al., 
2007), the best characterized of which is the Wnt/-catenin signal-
ing, also known as the “canonical” pathway. In this pathway, 
in the absence of ligands, the constitutively active kinase GSK-3  
Activation and disruption of Wnt/-catenin sig-naling both result in cartilage breakdown via unknown mechanisms. Here we show that 
both WNT-3A and the Wnt inhibitor DKK1 induced de- 
differentiation of human articular chondrocytes through 
simultaneous activation of -catenin–dependent and 
independent responses. WNT-3A activates both the 
-catenin–dependent canonical pathway and the Ca2+/ 
CaMKII noncanonical pathways, with distinct transcrip-
tional targets. WNT-3A promotes cell proliferation and 
loss of expression of the chondrocyte markers COL2A1, 
Aggrecan, and SOX9; however, proliferation and AXIN2  
up-regulation are downstream of the canonical pathway 
and are rescued by DKK1, whereas the loss of differen-
tiation markers is CaMKII dependent. Finally, we showed 
that in chondrocytes, the Ca2+/CaMKII-dependent and 
-catenin–dependent pathways are reciprocally inhibi-
tory, thereby explaining why DKK1 can induce loss of 
differentiation through de-repression of the CaMKII path-
way. We propose a novel model in which a single WNT 
can simultaneously activate different pathways with 
distinct and independent outcomes and with reciprocal 
regulation. This offers an opportunity for selective pharma-
cological targeting.
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through activation of CaMKII, and by DKK1 through inhibi-
tion of the canonical pathway and consequent de-repression of 
the CaMKII pathway.
Results
Biological events associated with  
WNT-3A treatment of primary  
articular chondrocytes
WNT-3A is a prototypical, well-characterized activator of the 
-catenin–dependent canonical pathway (Shimizu et al., 1997), 
which has an established role in arthritis (Nakamura et al., 2005), 
and it is expressed in articular cartilage (Fig. S1). Taking advan-
tage of the availability of WNT-3A as recombinant protein, we 
investigated the effects of this ligand on the proliferation, differ-
entiation, and extracellular matrix production of articular chon-
drocytes. Treatment of primary porcine articular chondrocytes 
with 100 ng/ml of recombinant WNT-3A over a 3-d time course 
resulted in a statistically significant increase of cell proliferation 
compared with vehicle control (Fig. 1 A). The proliferative effect 
of WNT-3A was confirmed in adult human articular chondro-
cytes (AHACs), where the proliferation marker PCNA was up-
regulated 24 h after stimulation with WNT-3A (Fig. 1 B).
We then compared the expression of chondrocyte-lineage 
markers by confluent primary AHACs treated with either 
WNT-3A or vehicle control. COL2A1, Aggrecan, and SOX9 
mRNA were statistically significantly down-regulated after 
WNT-3A treatment (Fig. 1 C). The chondrocyte hypertrophy 
marker MMP13 was also down-regulated. Other genes rel-
evant to cartilage homeostasis/biology including COL1A1, 
MMP-3, and ADAMTS5 (Goldring, 2006) were unchanged. The 
main function of articular chondrocytes is the production of a 
specialized extracellular matrix rich in highly sulphated GAGs, 
which provide the elastic biomechanical properties required 
for motion and weight bearing. Therefore, to test whether 
WNT-3A affected this important function of chondrocytes, 
we exploited the capacity of chondrocytes to produce large 
amounts of such matrix when cultured in 3D micromasses. 
Treatment of AHAC micromasses with 100 ng/ml of WNT-3A 
for 4 d induced a statistically significant decrease in the accumu-
lation of highly sulphated GAGs, as evaluated by Alcian blue 
staining and spectrophotometric quantitation (Fig. 1 D; De Bari 
et al., 2001). Collectively, these findings indicate that WNT-3A 
stimulation activates proliferation and de-differentiation of 
articular chondrocytes.
We confirmed the validity of these data in vivo using a 
well-established model that measures the capacity of chondro-
cytes to form hyaline-like cartilage when implanted ectopically 
in nude mice (Dell’Accio et al., 2001). To provide prolonged 
WNT-3A stimulation of the chondrocytes in vivo, we co- 
injected freshly isolated porcine articular chondrocytes with 
10% of growth-arrested L cells stably overexpressing WNT-3A 
(L-WNT-3A), or L cells as control. Growth arrest of L cells 
was successfully achieved by mitomycin C treatment (Fig. 2, 
A and B), without compromising their capacity to secrete bio-
logically active WNT-3A for at least 14 d (Fig. 2 C). Indeed, 
conditioned medium from L-WNT-3A cells that had been 
phosphorylates -catenin within a destruction complex, ad-
dressing it for degradation through the proteasome pathway 
(Logan and Nusse, 2004). The engagement of some members 
of the Wnt family, such as WNT-1 and WNT-3A (Hinck et al., 
1994;Shimizu et al., 1997) with Frizzled (FZD) receptors and 
the coreceptors low-density lipoprotein receptor-related receptor 
5/6 (LRP5/6), results in the disruption of the destruction com-
plex, accumulation of -catenin in the cytosol, and its migra-
tion in the nucleus, where -catenin interacts with T cell factor 
(TCF)/lymphoid enhancer–binding factor (LEF) transcription 
factors and supports the transcription of target genes (Molenaar 
et al., 1996). Other Wnts, such as WNT-5A and WNT-11 (Kühl 
et al., 2000), can instead activate other signaling cascades, gener-
ally referred as “noncanonical” pathways, such as the planar cell 
polarity pathway (PCP) and the Ca2+/CaMKII pathways (Sheldahl 
et al., 1999; Kühl et al., 2000; Semenov et al., 2007).
Activation of the canonical Wnt pathway is required and 
sufficient for embryonic joint specification (Hartmann and Tabin, 
2001; Guo et al., 2004), and both canonical and noncanonical 
Wnt signaling regulate morphogenesis, proliferation, cell specifi-
cation, and differentiation within the developing skeleton (Church 
et al., 2002; Enomoto-Iwamoto et al., 2002; Yang et al., 2003; 
Koyama et al., 2008).
In adult life, modulation of Wnt signaling has an important 
role in cartilage homeostasis. We demonstrated enhanced acti-
vation of the canonical Wnt pathway in osteoarthritic cartilage 
in humans (Dell’Accio et al., 2001) and after cartilage injury in 
mice (Dell’Accio et al., 2008; Eltawil et al., 2009). In addition, 
a loss of function polymorphism in the SFRP3 gene, encod-
ing for a soluble Wnt inhibitor (Leyns et al., 1997; Wang et al., 
1997), has been linked to an increased susceptibility to develop 
OA (Loughlin et al., 2004; Lories et al., 2007). These data, to-
gether with other in vivo and in vitro experimental evidence, 
suggest that an over-activation of the -catenin–dependent/Wnt 
pathway might be involved in OA pathogenesis (Schett et al., 
2008; Luyten et al., 2009).
However, the results of functional studies using mouse ge-
netics contrast with each other and are difficult to interpret. For 
instance, both repression and forced activation of the canonical 
Wnt signaling resulted in chondrodysplasia in embryonic life 
(Akiyama et al., 2004) and in OA development postnatally 
(Lories et al., 2007; Chen et al., 2008; Koyama et al., 2008; Zhu 
et al., 2008, 2009).
We demonstrated that the prototypical canonical activa-
tor WNT-3A and the inhibitor of the canonical pathway DKK1 
both induce down-regulation of cartilage phenotypic markers 
and reduction of glycosaminoglycan (GAG)-rich extracellular 
matrix in vitro. Although the fact that an activator and an in-
hibitor of the canonical Wnt pathway both lead to the same 
outcome is very surprising, nevertheless it is in keeping with 
the in vivo data mentioned previously and provided a conve-
nient system to dissect the underpinning molecular mecha-
nisms. We therefore used this system to propose a new model 
according to which WNT-3A can simultaneously activate the 
-catenin–dependent and CaMKII-dependent signaling, each 
with specific outcomes; reciprocal inhibition of these two 
pathways explains how differentiation is induced by WNT-3A 
553Wnt noncanonical signal in chondrocyte homeostasis • Nalesso et al.
WNT-3A mediates proliferation of  
AHACs via the -catenin–dependent 
pathway and their de-differentiation via  
a -catenin–independent mechanism
WNT-3A is known to activate the canonical Wnt pathway in a 
variety of cells. We therefore set out to confirm the activation of 
this pathway by WNT-3A in AHACs. Treatment with 100 ng/ml 
recombinant WNT-3A resulted in accumulation of -catenin 
(Fig. 3 A), activation of the SUPER8XTOPFlash reporter assay 
(Fig. 3 B), and a 250-fold up-regulation of the endogenous target 
gene AXIN2 (Fig. 3 C), which is indicative of activation of the 
-catenin–dependent canonical pathway (Yan et al., 2001).
To confirm that the observed AHAC phenotypic changes 
were caused by the activation of the canonical pathway, primary 
growth-arrested for 2 wk was able to activate the TCF/LEF1 
reporter assay SUPER8XTOPFlash (Veeman et al., 2003) in 
porcine articular chondrocytes. 2 wk after the injection, the wet 
weight of the cartilage implants retrieved from mice injected 
with chondrocytes plus L-WNT-3A cells was statistically 
significantly higher compared with that of implants obtained 
from chondrocytes co-implanted with control L cells (Fig. 2, 
H and I) and statistically significantly less differentiated, as 
demonstrated by a weaker staining with safranin O (SO; Fig. 2, 
D–G, J, and K), which confirms that WNT-3A also mediated 
proliferation and loss of chondrocyte phenotype in an in vivo 
system. Similar results were obtained with primary AHACs 
(Fig. S2), thereby confirming that this biological outcome is 
conserved across mammals.
Figure 1. WNT-3A induces chondrocyte proliferation and de-differentiation in vitro. (A and B) 100 ng/ml WNT-3A stimulated proliferation of primary 
chondrocytes in vitro as evaluated by an [H3]thymidine incorporation assay in porcine articular chondrocytes (A; n = 6) and by up-regulation of the prolif-
eration marker PCNA in primary AHACs by quantitative PCR (Q-PCR) (B; n = 4). (C and D) WNT-3A–induced down-regulation of the differentiation markers 
COL2A1, Aggrecan, SOX9, and MMP13, as evaluated by Q-PCR (C; n = 6), and reduced the accumulation of highly sulphated GAG in primary AHACs 
(D; by Alcian blue staining and spectrophotometric quantification; n = 4). Gene expression values are reported as a percentage of up- or down-regulation 
compared with control (100%, broken line in the graph). Statistical analysis was performed with an unpaired t test. Error bars indicate mean ± SEM. 
*, P < 0.05; **, P < 0.005; ***, P < 0.0005.
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Figure 2. WNT-3A induces proliferation and de-differentiation of articular chondrocytes in vivo. (A and B) WNT-3A induced chondrocyte de-differentia-
tion in vivo in an ectopic cartilage formation assay. Isolated porcine articular chondrocytes were co-injected intramuscularly in nude mice together with 
either L cells stably expressing WNT-3A (L-WNT3A) or control L cells (L cells; 12 injections per condition). Before injection, L cells and L-WNT-3A cells 
were growth-arrested by mitomycin C treatment. To confirm growth arrest, 2 d after treatment, a sample of cells with or without mitomycin C treatment was 
detached and counted (A; n = 4). Mitomycin C–treated cells stopped proliferating. One additional well was kept in culture for 14 d. The cells persisted but 
never reached confluency (B). Bar, 10 µm. (C) To confirm that mitomycin C growth-arrested L-WNT-3A cells still produced biologically active WNT-3A, the 
conditioned medium (from the last change of medium) obtained 14 d after mitomycin C treatment was tested for the ability to activate the SUPER8XTOPFlash 
reporter assay in porcine articular chondrocytes. Indeed, conditioned medium from L-WNT-3A cells, but not from control cells, activated the SUPER8XTOP-
Flash reporter. The mutagenized SUPER8XFOPFlash vector was used to control for specificity (n = 4). (D–K) SO staining of cartilage implants obtained by 
the co-injection of porcine articular cartilage with L cells (D) or L-WNT-3A cells (E) in nude mice. Cartilage implants obtained from porcine articular chondro-
cytes co-injected with L-WNT-3A cells are on average larger (H and I) and less differentiated (J and K), as shown by a decreased SO staining in comparison 
with controls. Grayscale digital images from SO staining were used to calculate and compare the mean intensity of the staining and, after thresholding, the 
percentage of the total implant area that was positive for SO (n = 12 per condition). M, muscle; I, implant; RLU, relative luminescence unit. An unpaired 
t test was used for statistical evaluation. Error bars indicate mean ± SEM. *, P < 0.05; **, P < 0.005; ***, P < 0.0005.
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DKK1, in the absence of WNT-3A, promoted by itself a down-
regulation of COL2A1 and Aggrecan, similar to that induced by 
WNT-3A, and up-regulation of MMP13, although, as expected, 
it did reduce AXIN2 and PCNA mRNA expression (Fig. 3 J).
The finding that DKK1 not only did not rescue WNT-3A–
induced loss of phenotypic markers but, on its own, promoted 
it, suggests that although proliferation and AXIN2 up-regulation 
are driven by activation of the canonical Wnt pathway, the loss of 
phenotypic markers and of extracellular matrix is regulated through 
a different pathway that is antagonized by the canonical one. 
To explain the apparent paradox that WNT-3A and DKK1 have 
the same effect, we hypothesized that, under our experimental 
AHACs were treated with either 100 ng/ml WNT-3A alone or 
in combination with 100 ng/ml of recombinant DKK1, which 
specifically inhibits the -catenin–dependent pathway by bind-
ing to LRP coreceptors and preventing their association with 
FZDs (Mao et al., 2001). Co-treatment with DKK1 reverted the 
WNT-3A–induced up-regulation of AXIN2, PCNA, and MMP13 
(Fig. 3, D–F), but, surprisingly failed to rescue the down-regulation 
of COL2A1, Aggrecan, and SOX9 mRNA (Fig. 3, G–I). To 
investigate whether this was caused by excessive, exogenous 
WNT-3A stimulation, we investigated whether treatment with 
DKK1 alone, in the absence of exogenous WNT-3A, modified 
the phenotype of AHACs. Strikingly, treatment of AHACs with 
Figure 3. Inhibition of Wnt canonical path-
way with DKK1 does not rescue the loss of the 
chondrocyte phenotype. (A–C) WNT-3A acti-
vates the Wnt canonical pathway in AHACs. 
(A) Western blotting for -catenin in the 
cytoplasmic fraction of AHACs treated with 
100 ng/ml WNT-3A or vehicle control for 24 h. 
(B) WNT-3A activated the SUPER8TOPFlash 
reporter assay in P0 AHACs after 24 h of 
stimulation (n = 3). (C) WNT-3A up-regulated 
the expression of the endogenous Wnt canon-
ical target gene AXIN2 in AHACs as evalu-
ated by Q-PCR. Values were normalized for 
the housekeeping gene -actin. (D–I) Primary 
AHACs were treated for 24 h with 100 ng/ml 
of recombinant WNT-3A or DKK1, alone or 
in combination, and were subjected to gene 
expression analysis by PCR. Blockade of the 
Wnt canonical pathway by DKK1 rescued the 
modulation of AXIN2, PCNA, and MMP13 
mRNA (D–F) but not the down-regulation of 
COL2A1, Aggrecan, and SOX9 (G–I). (J) In 
the absence of exogenous WNT-3A, treat-
ment with 100 ng/ml DKK1 resulted, as 
expected, in down-regulation of the mRNA 
levels of AXIN2 and PCNA, but also in a 
paradoxical down-regulation of COL2A1 and 
Aggrecan similar to that induced by WNT-3A. 
Q-PCR data, n = 6. Gene expression values 
are reported as a percentage of up- or down-
regulation compared with control (100% is 
indicated by the broken line in the graph). 
Data were analyzed with an unpaired t test. 
Error bars indicate mean ± SEM. *, P < 0.05; 
**, P < 0.005.
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conditions, the modulation of AXIN2, PCNA, and MMP13 
and chondrocyte proliferation are dependent on the Wnt–-
catenin canonical pathway, whereas the WNT-3A–mediated down- 
regulation of COL2A1 and Aggrecan are -catenin independent.
WNT-3A simultaneously activates the 
canonical and the Ca2+/CaMKII-dependent 
Wnt pathways in chondrocytes in a  
dose-dependent manner
We therefore hypothesized that WNT-3A induces loss of chon-
drocyte differentiation through activation of a noncanonical 
Wnt pathway. We focused on the Wnt-Ca2+/CaMKII path-
way because it has been shown to be active in chicken epiphy-
seal cartilage (Taschner et al., 2008) and to mediate Wnt 
signaling in zebrafish and Xenopus embryos (Slusarski et al., 
1997a,b; Sheldahl et al., 1999; Kühl et al., 2000) antagonizing 
-catenin. Therefore, to test whether WNT-3A activates the 
noncanonical Ca2+/CaMKII-dependent pathway, we treated 
primary AHAC cultures with increasing doses of WNT-3A 
while monitoring calcium mobilization (as a readout of the 
activation of the Ca2+-dependent pathway) and AXIN2 expres-
sion (as a readout for the activation of the canonical pathway). 
Figure 4. WNT-3A promotes intracellular Ca2+-mediated phosphorylation of CaMKII and its nuclear translocation. (A) WNT-3A caused calcium mobi-
lization in AHACs, particularly at low doses. Primary AHACs were treated with different amounts of recombinant WNT-3A or vehicle control for 5 min 
and then subjected to fluorometric determination of calcium mobilization (n = 9). (B) WNT3A-induced calcium mobilization assay in primary AHACs is 
G protein dependent. AHACs were preincubated overnight at 37°C with 1 µg/ml of the G protein inhibitor PTX and then treated for 5 min with 100 ng/ml 
of WNT-3A or vehicle control. PTX treatment blocked calcium mobilization induced by WNT-3A (n = 6). (C) Q-PCR for AXIN2 mRNA in primary chondro-
cytes exposed for 24 h to different doses of recombinant WNT-3A. WNT-3A induced dose-dependent up-regulation of AXIN2 in primary AHACs (n = 3). 
(D) WNT-3A induced nuclear accumulation of the phosphorylated form of CaMKII. Immunofluorescence staining for pCaMKII in P0 AHACs stimulated for 
24 h with WNT-3A in combination with either the CaMKII inhibitor KN93 or its inactive analogue KN92 (both 10 µM). Bar, 20 µm. (E–I). Quantification of 
the pCaMKII fluorescence intensity in the nuclear and in the cytoplasmic fractions of stimulated AHACs. The pixel intensity profile was plotted over a linear 
section of a whole cell (E and F). The nuclear and cytoplasmic fluorescence intensity was then calculated as the area under the curve (G–I). (J) WNT3A 
promotes phosphorylation of CaMKII in T286 at 15 min and 1 h from WNT-3A stimulation. RFU, relative fluorescence unit; RFI, relative fluorescence inten-
sity. Data were analyzed with an unpaired t test except in C, where a Kruskal Wallis with a Dunns post-test was used. Error bars indicate mean ± SEM. 
*, P < 0.05; **, P < 0.005; ***, P < 0.0005.
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we repeated the same experiment using sFRP1 as a Wnt inhibi-
tor. We chose sFRP1 because it is known to bind and inhibit 
several Wnts, including WNT-3A (Galli et al., 2006; Wawrzak 
et al., 2007), preventing their interaction with FZD receptors. 
sFRP1 treatment prevented WNT-3A–induced intracellular cal-
cium accumulation, but, in contrast to DKK1, did not induce 
Ca2+ mobilization on its own, thereby confirming that Ca2+ mo-
bilization induced by DKK1 is caused by selective inhibition 
of the canonical pathway and consequent de-repression of the 
Ca2+/CaMKII pathway (Fig. S3).
Distinct effects in chondrocytes of the 
WNT-3A–mediated activation of -catenin 
and CaMKII pathways
Having demonstrated that WNT-3A can signal simultaneously 
through two intracellular pathways, we set out to discriminate 
CaMKII-dependent from -catenin–dependent transcriptional 
targets. To this end, we treated chondrocytes with WNT-3A 
in the presence of either the CaMKII inhibitor KN93 or the 
inactive compound KN92. As expected, WNT-3A induced a 
significant down-regulation of COL2A1, Aggrecan, and SOX9 
mRNA compared with control, but CaMKII blockade with 
KN93 resulted in a statistically significant rescue of COL2A1 
and SOX9 expression (Fig. 6. B and D), which demonstrated 
that WNT-3A–induced chondrocyte de-differentiation is at least 
in part CaMKII dependent. In contrast, KN93 did not rescue 
the down-regulation of MMP13 mRNA (Fig. 6 E). Therefore 
WNT-3A up-regulates AXIN2 and PCNA through the canonical 
pathway and down-regulates SOX9 and COL2A1 in a CaMKII-
dependent manner (Fig. 7, A and B).
In contrast, nonspecific forced Ca2+ mobilization using 
phorbol 12-myristate 13-acetate (PMA) resulted in down-
regulation of AGGRECAN but not SOX9 or COL2A1 (Fig. S4). 
In keeping with our hypothesis, WNT-3A elicited activation 
of both pathways; notably, Ca2+ mobilization occurred pref-
erably at low doses and AXIN2 up-regulation at higher doses 
(Fig. 4, A and C).
In zebrafish and Xenopus embryos, it was shown that the 
Ca2+/CaMKII pathway signals in a G protein–dependent man-
ner (Slusarski et al., 1997a; Sheldahl et al., 1999; Kühl et al., 
2000). In our experimental system, pertussis toxin (PTX), a Gi, 
G0, and Gt protein inhibitor (Slusarski et al., 1997a; Sheldahl 
et al., 1999), efficiently blocked WNT-3A–induced calcium 
mobilization (Fig. 4 B). Next, to evaluate the involvement of 
CaMKII, we treated AHACs with 100 ng/ml WNT-3A or ve-
hicle control for 24 h and stained the monolayers with an anti-
body to detect the activated, phosphorylated form of CaMKII 
(Soderling, 1999). PhosphoCaMKII staining was increased in 
WNT-3A–treated samples with increased nuclear localization, 
confirming the activation of this pathway (Fig. 4, D–I). Such 
phosphorylation was abrogated in the presence of the selective 
CaMKII inhibitor KN93 (Fig. 4 D). CaMKII phosphorylation 
was also detected by Western blotting analysis, after 15 min 
and 1 h from the addition of WNT-3A to the cells (Fig. 4 J). 
Altogether, our data indicate that exogenous application of 
WNT-3A is sufficient to dose dependently activate both the ca-
nonical -catenin–dependent and noncanonical Ca2+/CaMKII-
dependent pathways (see Fig. 7, A and B).
Wnt canonical and Wnt-CaMKII 
noncanonical pathways are reciprocally 
inhibitory in AHACs
In Xenopus, the Wnt Ca2+/CaMKII pathway has been shown 
to inhibit the Wnt–-catenin–dependent pathway (Sheldahl 
et al., 1999; Kühl et al., 2000). To investigate the interaction 
between the CaMKII pathway with the Wnt canonical pathway 
after WNT-3A stimulation, we treated confluent passage 0 (P0) 
AHACs with 100 ng/ml WNT-3A and either the selective CaM-
KII inhibitor KN93 or its inactive analogue KN92 (both 10 µM) 
for 24 h. CaMKII inhibition by KN93 significantly increased the 
WNT-3A–induced up-regulation of AXIN2 mRNA (Fig. 5 A).
In contrast, KN92, which is structurally similar to KN93 but 
does not inhibit CaMKII (Marley and Thomson, 1996), did 
not alter the expression of AXIN2 (Fig. 5 A). To study if the 
Wnt/-catenin pathway modulates the Wnt-Ca2+/CaMKII path-
way, we treated AHACs with WNT-3A and DKK1, alone or in 
combination. Both WNT-3A and DKK1 stimulation resulted in 
statistically significant activation of Ca2+ mobilization, which 
was further increased when DKK1 and WNT-3A were used 
together, thereby demonstrating that the selective inhibition of 
the canonical pathway enhances the activation of the Ca2+ mo-
bilization (Fig. 5 B).
Collectively, our data demonstrate reciprocal inhibition 
of the Wnt–-catenin and Wnt-Ca2+/CaMKII pathways after 
WNT-3A stimulation in articular chondrocytes, and that the inhibi-
tion of one causes de-repression of the other (see Fig. 7, C–E)
To gain a better insight into this mechanism and specifi-
cally examine whether the selectivity of the blockade for the 
canonical pathway was essential for Ca2+ mobilization or if 
general out-titration of Wnts also induced Ca2+ mobilization, 
Figure 5. Wnt canonical and Wnt-CaMKII noncanonical pathways are 
reciprocally inhibitory in AHACs. (A) Q-PCR for AXIN2 of primary AHACs 
treated with 100 ng/ml WNT-3A in the presence of the CaMKII inhibitor 
KN93 or its inactive analogue KN92 (10 µM). (B) DKK1 promoted intracel-
lular calcium accumulation in P0 AHACs. The inhibition of the canonical 
pathway with DKK1 enhanced intracellular calcium accumulation induced 
by WNT-3A. In all the experiments, n = 4. Data in A were analyzed with 
ANOVA; data in B were analyzed with an unpaired t test. Error bars indi-
cate mean ± SEM. *, P < 0.05; ***, P < 0.0005.
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Figure 6. Inhibition of the Ca2+/CaMKII pathway rescued the loss of 
COL2A1 and SOX9 mRNA expression in AHACs. (A) Blockade of CaMKII 
with KN93 did not alter the basal levels of Aggrecan, COL2A1, and 
SOX9. Primary AHACs were treated for 24 h with 10 µM KN93 or its in-
active analogue KN92. (B–E) CaMKII blockade rescues WNT-3A–induced 
down-regulation of COL2A1 and SOX9 mRNA. Primary AHACs were cul-
tured for 24 h in the presence of WNT-3A or vehicle control, and either 
the CaMKII inhibitor KN93 or the inactive control KN92. Gene expression 
was evaluated by Q-PCR. The values were normalized for -actin and 
expressed as a percentage of the KN92-treated group (100% is indicated 
by the broken line in the graphs; n = 6). Statistical analysis was performed 
with an unpaired t test. Error bars indicate mean ± SEM. *, P < 0.05; 
**, P < 0.005.
This, and the fact that instead CaMKII blockade rescued the 
expression of COL2A1 as well as SOX9, suggests that the 
WNT-3A–induced effects on these three genes rely specifically 
on the CaMKII-dependent Ca2+-pathway.
Discussion
We have demonstrated that chondrocyte exposure to exoge-
nous WNT-3A can simultaneously activate both the -catenin– 
dependent and the G protein–mediated Ca2+/CaMKII/pathways, 
which are in equilibrium because of reciprocal inhibition. These 
two pathways modulate the transcription of distinct target genes 
involved in different biological processes: WNT-3A promotes 
chondrocyte proliferation through -catenin and differentiation 
through CaMKII. According to our model, blockade of the 
canonical/-catenin pathway will also cause articular-chondrocyte 
de-differentiation through de-repression of the CaMKII path-
way (Fig. 7, A and B).
This model may help explaining contradictions in the cur-
rent literature. In particular, both activation and disruption of 
the canonical Wnt signaling result in chondrodysplasia with 
delayed maturation of chondrocytes (Enomoto-Iwamoto et al., 
2002; Akiyama et al., 2004) and in cartilage breakdown in adult-
hood (Chen et al., 2008; Koyama et al., 2008; Zhu et al., 2008, 
2009). Similarly, in the mouse embryo (Yamaguchi et al., 1999; 
Yang et al., 2003), both the overexpression and the knockout 
of WNT-5A, which in zebrafish and Xenopus has been shown 
to activate the Ca2+/CaMKII pathway (Slusarski et al., 1997b; 
Kühl et al., 2000), result in a similar phenotype of chondrodys-
plasia, in both cases with reduced chondrocyte proliferation and 
hypertrophic maturation (Yamaguchi et al., 1999; Yang et al., 
2003). Although this phenotype, in vivo, may be partially deter-
mined by compensatory mechanisms involving modulation of 
the Ihh–PTHrP pathway, COL2A1 expression was up-regulated in 
the growth plate of WNT-5A knockout mice and down-regulated 
in mice overexpressing WNT-5A under the transcriptional con-
trol of the collagen type 2 promoter (Yang et al., 2003). In ad-
dition, in vitro, WNT-5A dose-dependently down-regulated the 
activity of a COL2A1 reporter in mouse chondrocytes. Impor-
tantly, this study showed that WNT-1, a well validated canoni-
cal Wnt, could also decrease COL2A1 reporter activity, though 
in a TCF-independent manner, because overexpression of TCF1 
failed to achieve the same result (Yang et al., 2003). This may 
suggest that WNT-3A may not be the only canonical Wnt to 
signal through multiple pathways.
In keeping with our data, Taschner et al. (2008) found that 
forced activation of CaMKII in the chick epiphyseal cartilage 
resulted in down-regulation of cell-cycle regulators and accel-
eration of hypertrophic differentiation, which is notoriously as-
sociated with down-regulation of COL2A1 and SOX9 (Lefebvre 
et al., 1998; Taschner et al., 2008). However, care must be applied 
in comparing our results with Taschner et al. (2008) because of 
the intrinsically different biology of epiphyseal chondrocytes, 
which are destined to undergo hypertrophic differentiation and 
eventually be replaced by bone, and the articular chondrocytes, 
which are resistant to hypertrophy and to endochondral bone 
formation. In addition, in Taschner et al. (2008), proliferation is 
559Wnt noncanonical signal in chondrocyte homeostasis • Nalesso et al.
exclude that in our system, G protein activation may be indirect, 
e.g., through the activation of a different GPCR.
A separate issue is as to whether, in our system, individual 
FZD receptors can activate both pathways, or if the simultaneous 
activation of canonical and CaMKII pathways is caused by the 
coexpression, on chondrocytes, of FZD receptors with different 
signaling specificity. Slusarski et al. (1997a) demonstrated that in 
zebrafish, expression of rat frizzled 2 receptor (Rfz-2), but not 
Rfz-1, increased intracellular calcium accumulation in a way that 
was enhanced by the coexpression of Xenopus Wnt-5a (Xwnt-5a). 
In addition, in a mammalian cell line, Xwnt-5a but not Xwnt-8 
stimulated calcium accumulation via Rfz-2 in a PTX-sensitive 
way (Liu et al., 1999). Subsequently, Kühl et al. (2000) demon-
strated that in Xenopus, WNT-5A–induced Ca2+ mobilization re-
sulted in CaMKII activation in a FZD-specific manner. Only 
some FZD receptors were able to signal through CaMKII, and 
such signal was also strictly ligand-specific.
We have demonstrated that AHACs express different FZD 
receptors (Fig. S5) known to mediate both the canonical (Gazit 
et al., 1999; Terasaki et al., 2002; Karasawa et al., 2002; Kemp 
et al., 2007) and the Ca2+-dependent pathways (Kühl et al., 
2000; Robitaille et al., 2002; Nishita et al., 2010). Therefore, it 
is possible that the receptor repertoire of chondrocytes may de-
termine the balance of the WNT-3A signaling.
Alternatively we cannot exclude the possibility that mech-
anisms downstream of FZD receptors may activate CaMKII: 
driven by noncell autonomous mechanisms including secretion 
of Ihh and consequent PTHrP signaling. With all these limita-
tions in comparing the experimental setups, this paper and a 
recent similar paper from Li et al. (2011), in which overexpres-
sion of constitutively active CaMKII was complemented by loss 
of function experiments, show the role of this kinase in the ini-
tiation of hypertrophy, a process that is associated with the loss 
of stable chondrocyte markers including SOX9 and COL2A1 
(Lefebvre et al., 1998).
The reciprocal inhibition of the canonical and CaMKII-
dependent pathways activated by WNT-3A may represent a hub 
through which different stimuli active in cartilage and known to 
influence CaMKII can dramatically influence the outcome of 
Wnt signaling by switching between -catenin and CaMKII-
dependent target genes. Such stimuli include inflammatory mole-
cules (Pritchard and Guilak, 2006; Racioppi and Means, 2008), 
biomechanics (Valhmu and Raia, 2002; Shimazaki et al., 2006), 
and PTHrP activity (Taschner et al., 2008).
Although we and others (Slusarski et al., 1997a; Sheldahl 
et al., 1999; Kühl et al., 2000) have shown that Ca2+/CaMKII 
activation is G protein–coupled receptor (GPCR) dependent, it 
is still unclear how Wnts activate G proteins. Based on the simi-
larity between FZD receptors and other GPCR (Wang et al., 
2006), it is tempting to postulate that, in the absence of DKK-
engaged LRP, FZD receptors may function as GPCRs (Wang 
et al., 2006; Koval and Katanaev, 2011). However, we cannot 
Figure 7. Simultaneous activation and re-
ciprocal inhibition of -catenin– and CaMKII– 
dependent pathways in AHACs. (A and B) In 
AHACs, WNT-3A up-regulates AXIN2 ex-
pression and proliferation through the Wnt 
canonical pathway (A), but induces loss of 
differentiation via a G protein–mediated Ca2+/
CaMKII–dependent pathway (B). (C–E) These 
two pathways are reciprocally inhibitory and 
in equilibrium. Therefore, either exogenous 
WNT-3A (C) or blockade of the canonical path-
way with DKK1 (D–E) will both result in loss of 
chondrocyte phenotype.
JCB • VOLUME 193 • NUMBER 3 • 2011 560
Wnt stimulation and avoiding concerns related, for instance, to 
the role of -catenin in cancer development (Morin et al., 1997; 
Sunaga et al., 2001).
Materials and methods
Cartilage harvest and chondrocyte isolation
Adult human articular cartilage was obtained from patients who underwent 
joint replacement for knee OA after obtaining informed consent. The carti-
lage samples were provided by P. Achan (Barts and the London National 
Health Service Trust, London, England, UK). All procedures were approved 
by the East London and The City Research Ethics Committee 3.
Cartilage tissue was dissected from preserved areas of the femoral 
condyles and the patellar groove. The cartilage was sliced full thickness, 
excluding the mineralized cartilage and the subchondral bone. From each 
sample, one full thickness specimen was processed for histological grad-
ing, and the rest was used for chondrocyte isolation. The aliquot destined to 
chondrocyte isolation was washed twice in high-glucose DME (DME/F-12 
1:1 plus GlutaMax; Invitrogen) containing 10% FBS, 1 mM sodium pyru-
vate (NaPyr), and 2% antibiotic antimycotic solution (Invitrogen). Cartilage 
was then digested for 30 min at 37°C in 1 mg/ml pronase (Roche) and 
then overnight at 37°C in 1 mg/ml collagenase P (Roche) prepared in com-
plete medium (same composition as above, with 1% antibiotic/antimycotic 
solution) under agitation. The AHACs recovered from the digestion were 
then resuspended in complete medium and seeded at a density of 10,000 
cells/cm2. The cells were cultured at 37°C in a humidified atmosphere 
containing 5% CO2. The aliquot destined for histological scoring was fixed 
in 4% paraformaldehyde in PBS at pH 7.4, paraffin embedded, sectioned, 
stained, and scored for features of OA as described previously (Mankin 
et al., 1971, Dell’Accio et al., 2008). Only cells obtained from samples 
with a Mankin score <4 were used for subsequent experiments. All experi-
ments were performed using freshly isolated or confluent P0 cells.
Porcine chondrocytes were isolated from the metatarsal joints of 
adult pigs obtained within 24 h of death from a local abattoir. The articular 
cartilage was dissected in sterile conditions and processed for cell isolation 
as described for human chondrocytes.
Titrated thymidine incorporation
Freshly isolated porcine articular chondrocytes were seeded at a density of 
6,000 cells/cm2 and left to attach overnight in standard culture conditions. 
The day after seeding and at all the time points analyzed, the cells were 
treated for 6 h with 100 ng/ml of recombinant WNT-3A (R&D Systems) or 
vehicle (0.1% BSA in PBS) in complete medium at 37°C. 2 Cu/µl/cm2 of 
[3H]thymidine was then added, and after 12 h of incubation, the cells were 
lysed in trichloroacetic acid. The radioactivity (recorded as counts per min-
ute) was measured using a 1900 Liquid Scintillation analyzer (Packard).
Gene expression analysis
Total RNA was extracted from AHACs using TRIzol reagent (Invitrogen) 
according to the manufacturer’s instructions. 500 ng of total RNA from 
each sample was reverse transcribed using Thermoscript Reverse transcrip-
tion kit (Invitrogen) with oligo dT primer. Quantitative and semiquantitative 
PCR was performed with hot-start DNA polymerase (QIAGEN) in the pres-
ence of 0.1× SYBR green (Sigma-Aldrich) and 0.2× ROX dye (Invitrogen) 
using, respectively, a T7900 HD or a 96 well GeneAmp PCR system 9700 
machine (Applied Biosystems). Primer sequences are listed in Table I.
SDS-PAGE and Western blotting
After treatment, cells were washed once in ice-cold PBS containing phos-
phatase and protease inhibitors (Roche). Total cell extracts were obtained 
by scraping the cells in extraction buffer (10 mM Hepes, 1.5 mM MgCl2, 
10 mM KCl, 0.5 mM DTT, and 0.05% NP-40, pH 7.9) and leaving the 
lysates on ice for 30 min. Protein concentration of the samples was deter-
mined by a bicinchoninic acid assay (Thermo Fisher Scientific).
The extracts were resolved by SDS-PAGE, and transferred to a 
nitrocellulose membrane (GE Healthcare). Human -catenin was detected 
with anti–-catenin rabbit monoclonal (diluted 1:1000; Cell Signaling 
Technology), whereas -actin was detected with anti–-actin mouse 
polyclonal antibody (diluted 1:10,000; Sigma-Aldrich), followed by in-
cubation with HRP-conjugated secondary antibodies (diluted 1:2,000; 
Santa Cruz Biotechnology, Inc.). Antibodies were diluted in 5% nonfat 
milk/0.01% Tween 20 in PBS. In the case of CaMKII and phospho-
CaMKII analysis, the membranes were blocked in 5% BSA/0.01% 
GSK3 inhibitor LiCl also down-regulated COL2A1 expression 
(Ryu et al., 2002; Ryu and Chun, 2006) in different systems, 
with the caveat that lithium is also an inhibitor of the inositol 
pathway (Berridge and Irvine, 1989). Hence, these data are dif-
ficult to interpret.
Whichever the mechanism, it is unlikely that, in our sys-
tem, the activation of the Ca2+/CaMKII pathway is indirect, as 
Ca2+ mobilization occurred as early as 5 min after the addition 
of WNT-3A.
Equally, although it cannot be completely excluded, it is 
unlikely that exogenous WNT-3A may have caused promiscuous 
activation of receptors, first because Ca2+ release took place par-
ticularly at low doses of WNT-3A, whereas -catenin activa-
tion was observed only at the higher doses; and second, because 
DKK1 also caused Ca2+ release and chondrocyte de-differentiation 
in the absence of exogenous WNT-3A (Figs. 3 J, 5 B, and 7, 
D and E), which cannot be explained by promiscuous receptor 
activation by supraphysiological levels of exogenous WNT-3A. 
Intriguingly, in addition, direct activation of the PKC pathway 
by WNT-3A was found in the ST2 cell line mediating osteo-
genesis (Tu et al., 2007).
In our system, activation of CaMKII was associated 
with its nuclear localization, which could be blocked with the 
CaMKII inhibitor KN93. A similar activation-dependent nu-
clear localization of phosphoCaMKII has been described in 
smooth muscle cells (Cipolletta et al., 2010) and very recently 
in epiphyseal chondrocytes (Li et al., 2011) in vivo. Nuclear 
localization of CaMKII is regulated by several factors including 
splicing of an NLS, phosphorylation of serines downstream of 
the NLS, and binding to anchoring and interacting molecules 
(Griffith et al., 2003). The specific function of the nuclear local-
ization in this context is not known; however, subcellular local-
ization of CaMKII has been shown to restrict/regulate substrate 
specificity in different cell types or in response to other signals 
(Griffith et al., 2003; Tsui et al., 2005). Therefore, it is tempting 
to speculate that CaMKII may have a nuclear function, either 
in mediating chondrocyte de-differentiation or in suppression 
of the canonical pathway. In this regard, it has been shown that 
CaMKII activation in colon cancer cells mediates nuclear ex-
port of TCF isoforms (Najdi et al., 2009).
One novel and important aspect of our study is that the 
-catenin–dependent pathway and the Ca2+/CaMKII noncanonical 
pathway have different transcriptional targets: AXIN2 and cell 
proliferation are specifically regulated by the canonical path-
way, whereas the loss of chondrocyte phenotype (COL2A1 
and SOX9) are mediated by the Ca2+/CaMKII arm of WNT-3A 
stimulation. This has important implications from the pharma-
cological point of view. In fact, for its role on cartilage and 
joint homeostasis, the Wnt signaling is an attractive therapeutic 
target. Unfortunately, the multitude of processes regulated by 
Wnts and the complexity of their regulation has long been a 
hurdle. Understanding how downstream biological events are 
individually regulated by Wnts in different cells represents an 
opportunity to achieve a higher degree of target specificity. 
Indeed, the availability of molecules and drugs that can selec-
tively interfere with either CaMKII or the canonical Wnt path-
way offers the possibility of targeting individual outcomes of 
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stained with SO according to standard protocols. All the sections were 
mounted in DPX (BDH chemicals). Images of the sections were taken with a 
microscope (BX61; Olympus) by using UPlan-Apochromat 4× NA 0.16 
and 20× NA 0.70 objective lenses. Images were acquired at room tem-
perature, with an F-View II (SIS; Olympus) camera and Cell P software. 
Three different parameters for each section were assessed by using ImageJ 
software: the area covered by the cartilage tissue, the mean of the intensity 
of the staining, and the percentage of the total area of the section with an 
intensity of staining equal to a fixed, thresholded value (130). The values 
were then averaged. In the case of implants obtained from porcine 
articular chondrocytes, one section per implant was analyzed. For the im-
plants obtained by human chondrocytes, five sections for each implant 
were analyzed, covering a total thickness of 350 µm.
The contrast of the images was enhanced using Photoshop 7.0 
for better rendering without altering the relationship of the target to the 
control images.
Calcium mobilization assay
Calcium mobilization was evaluated using Fluo-4-Direct kit (Invitrogen) in 
accordance to manufacturer’s specifications. In brief, P0 chondrocytes 
were labeled for 1 h (30 min at room temperature and 30 min at 37°C) 
with the Fluo-4-Direct calcium assay buffer containing Probenecid (Invitro-
gen), and were subjected to treatments with growth factors or inhibitors as 
indicated for individual experiments. After treatments, the fluorescence 
emitted by the cells (excitation wavelength 494 nm, emission wavelength 
516 nm) was recorded using a fluorometer (Galaxy; Fluo-Star). The fluores-
cence was expressed as relative fluorescence units.
Micromass culture and Alcian blue staining
Freshly isolated human articular chondrocytes were resuspended at a 
density of 2.0 × 107 cells/ml in complete medium, and micromass cultures 
were obtained by pipetting 20-µl drops of cell suspension into each well 
of a 24-well plate. The cells were left to attach for 3 h and then 1 ml of 
compete medium was added. 24 h later, micromasses were exposed to 
100 ng/ml of WNT-3A or vehicle for 4 d, changing medium every 48 h. 
Finally, micromasses were fixed and whole-mount stained with Alcian blue 
as described previously (De Bari et al., 2001). After proteoglycan extrac-
tion with 6 M guanidine HCl, the absorbance was read at 630 nm with 
a GENios spectrophotometer (Tecan). Images of the micromasses were 
acquired at room temperature with a camera (Coolpix 4500; Nikon), with 
the macro setting and daylight.
The contrast of the pictures was then modified with Photoshop 7.0 
for best graphic rendering, equally for the vehicle-treated and for the 
WNT-3A treated micromasses.
Tween 20 in PBS, and the antibodies (1:2,000 anti-CaMKII [Abcam]; 
1:1000 anti-pT286CaMKII [Cell Signaling Technology]) were diluted 
in the same buffer.
Transfections and reporter assay
Subconfluent AHACs and porcine articular chondrocytes were cotrans-
fected with SUPER8XTOP/FOPFlash TCF/LEF–firefly luciferase reporter vec-
tor (gift of R. Moon, University of Washington, Seattle, WA) and CMV-Renilla 
luciferase vector (in a ratio 1:10) by using Lipofectamine 2000 transfection 
reagent (Invitrogen) according to the manufacturer’s instructions. 24 h after 
transfection, the medium was replaced and the cells were stimulated for 24 h 
with recombinant WNT-3A 100 ng/ml (R&D Systems) or WNT-3A condi-
tioned medium at 37°C, 5% CO2. Luciferase activity was measured using 
the Dual Luciferase Reporter Assay System (Promega) and a TD-20/20 Lu-
minometer (Turner Designs). Firefly luciferase activity was normalized by 
Renilla luciferase activity and expressed as relative luciferase units.
Ectopic cartilage formation assay in vivo
The ectopic cartilage formation assay was performed as described pre-
viously (Dell’Accio et al., 2001). In brief, with a few modifications, for 
each injection 5 million freshly isolated porcine chondrocytes were mixed 
with either 500,000 growth-arrested (treated with 7.5 µg/ml of mitomycin 
C [Sigma-Aldrich] diluted in complete medium for 2 h at 37°C) L cells 
overexpressing WNT-3A (L-WNT-3A cells, American Type Culture Collec-
tion) or with the same amount of mitomycin C–treated control cells (L cells, 
American Type Culture Collection).
Each sample was resuspended in 50 µl of sterile PBS and injected 
intramuscularly in the posterior compartment of the thigh of 4-wk-old 
female CD1nu/nu mice (Dell’Accio et al., 2001). We performed 12 injec-
tions per condition (24 in total). The same experiment was replicated with 
human articular chondrocytes (n = 3 implants for each condition). Animals 
were maintained in isolator cages under an unrestricted diet. The animals 
were then killed after 2 wk and the cartilage implants were retrieved. 
All procedures were approved by the Local Ethics committee and the UK 
Home Office.
The implants were paraffin embedded for histological analysis.
Histology
Images of L cells treated with mitomycin C were captured with an inverted 
microscope (Eclipse TS100; Nikon) using a Plan-Fluor 10× 0.30 NA objec-
tive lens at room temperature. Images were acquired with a camera (Cool-
pix 4500; Nikon) and analyzed with Photoshop 7.0 (Adobe). 5-µm-thick 
sections were obtained from the center of the cartilage implants isolated 
from the nude mice, thereby representing the maximum sectional area, and 
Table I. Primer sequences used for quantitative and semiquantitative gene expression analysis
Gene Sense Antisense Length
-actin 5-CACGGCTGCTTCCAGCTC-3 5-CACAGGACTCCATGCCCAG-3 134 bp
ADAMTS-5 5-GACCGATGGCACTGAATGTA-3 5-TGTACAGCTGGAGTTGTCTCCT-3 145 bp
Aggrecan 5-GTTGTCATCAGCACCAGCATC-3 5-ACCACACAGTCCTCTCCAGC-3 509 bp
Axin-2 5-TACCGGAGGATGCTGAAGGC-3 5-CCACTGGCCGATTCTTCCTT-3 345 bp
Col1A1 5-GCCCTGTCTGCTTCCTGTAA-3 5-GGTTCAGTTTGGGTTGCTTG-3 104 bp
Col2A1 5-CTGCTCGTCGCCGCTGTCCTT-3 5-AAGGGTCCCAGGTTCTCCATC-3 432 bp
MMP-3 5-CAACCGTGAGGAAAATCGATGCAG-3 5-CGGCAAGATACAGATTCACGCTCAA-3 440 bp
MMP-13 5-ACGGACCCATACAGTTTGAATACAGC-3 5-CCATTTGTGGTGTGGGAAGTATCATC-3 360 bp
PCNA 5-GGAGAACTTGGAAATGGAAAC-3 5-CTGCATTTAGAGTCAAGACCC-3 548 bp
Sox9 5-GAACGCACATCAAGACGGAG-3 5-TCTCGTTGATTTCGCTGCTC-3 631 bp
WNT-3A 5-CCATCCTCTGCCTCAAATTC-3 5-TGGACAGTGGATATAGCAGCA-3 70 bp
FZD1 5-TTCAGCAGCACATTCTGAGG-3 5-CCTGCACACATTTTCCCTTT-3 154 bp
FZD2 5-TCACGGTCTACATGATCAAA-3 5-GCAACCTAAAAGTGAAATGG-3 266 bp
FZD3 5-GGATGATCAAAGAAGCAAAG-3 5-TTGAGCCGATGAGAACTACT-3 186 bp
FZD4 5-GACTTTGGAAGGAACCTTTT-3 5-TGAAACCCCGTCTCTACTAA-3 238 bp
FZD5 5-GGTTTGGTGCAGGTGAATTT-3 5-CTACAGCATGGGATAGGCACT-3 125 bp
FZD6 5-TTCGGCAGCTCACTAGGATT-3 5-CATCAGAAAATCTTGCCCAA-3 190 bp
FZD7 5-CTGGAGTTCTTTGAAATGTGCT-3 5-AAGGTTAGCTCCCATGATTCTC-3 133 bp
FZD8 5-CGGTTTGGGTATTCTTAATG-3 5-ACAGGGGTAAGCCTCTAAAC-3 215 bp
FZD9 5-AACACAGAGAAGCTGGAGAA-3 5-ACCACCAGTGACATGAAAAT-3 251 bp
FZD10 5-AGAAACCCTTCAGTGCTACA-3 5-AAAGTGTCTCTGCCAACCTA-3 205 bp
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Phospho CaMKII immunofluorescence
AHACs used for immunofluorescence were seeded on chamber slides (Lab-
Tek) and treated for 24 h with 100 ng/ml of recombinant WNT-3A in com-
bination with 10 µM KN92 or KN93 (EMD). The cells were then washed in 
PBS and fixed in 4% buffered PFA, pH 7.4, for 5 min at room temperature. 
Autofluorescence was quenched in 50 mM NH4Cl for 10 min. After 1 h 
of blocking in FBS diluted 1:5 in PBS/0.2% Triton X-100 (blocking buffer), 
sections were incubated overnight at 4°C with anti–phospho-CaMKII rab-
bit polyclonal antibody (Cell Signaling Technology) or rabbit IgG (Dako) 
as a negative control, diluted 1:200 in blocking buffer. After washing, 
cells were incubated with cy3-conjugated goat anti–rabbit antibody 1:300 
(Jackson ImmunoResearch Laboratories, Inc.) for 1 h. Slides were mounted 
in Mowiol (EMD), and images were acquired with a fluorescence micro-
scope (BX61; Olympus) using a Uplan-Fluor 40× NA 0.85 objective lens. 
Images were acquired at room temperature, by using an F-View II (SIS) 
camera and Cell P software. After acquisition and densitometric analysis 
(see the next paragraph), the contrast of the images was enhanced for 
best graphic rendering using Photoshop 7.0, all with the same param-
eters, without altering the relationship of the target to control the images. 
The fluorescence intensity was measured by using ImageJ software on the 
original photographs. The average pixel intensity profile (y axis: 0 = black, 
255 = white) was plotted over a linear section of a whole cell. The mean 
nuclear and cytoplasmic fluorescence intensity, obtained by the plot profile 
as shown in Fig. 4 E, were generated by analyzing 40 cells per field in 
duplicate for each condition.
Statistical analysis
Parametric data were compared with a t test. For multiple comparisons, 
we used analysis of variance (ANOVA) analysis, with a Dunnet post-test. 
Nonparametric values were analyzed by a Kruskal-Wallis test, with a 
Dunns post-test. P-values <0.05 were considered significant. *, P < 0.05; 
**, P < 0.005; ***, P < 0.0005. All the data in the graphs are expressed 
as mean ± SEM.
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Fig. S1 shows the expression of WNT-3A in human articular cartilage. Fig. S2 
shows that cartilage implants obtained by the co-injection of human articu-
lar chondrocytes with L cells overexpressing WNT-3A are bigger and less 
differentiated than controls. Fig. S3 shows that sFRP1 does not promote in-
tracellular calcium mobilization and partially blocks the ability of WNT-3A 
to increase intracellular calcium levels. Fig. S4 shows that PMA promotes 
intracellular calcium accumulation in articular chondrocytes and induces 
down-regulation of Aggrecan. Fig. S5 shows the gene expression levels of 
FZD receptors in human articular chondrocytes cultured in monolayer (P0) 
and in human cartilage explants. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201011051/DC1.
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